

Cyanobacterial Diversity: A Potential Source of Bioactive Compounds



Sunil K Dangi, Sarita Dubey and Santosh Bhargava*

Division of Microbiology, Government Motilal Science College, India

Submission: May 26, 2017; Published: June 28, 2017

*Corresponding author: Santosh Bhargava, Division of Microbiology, Department of Botany, Government Motilal Science College, Bhopal 462008 (M.P.) India, Email: santoshbhargava@hotmail.com

Abstract

Cyanobacteria grow and multiply in various aquatic ecosystems with varying environmental conditions. As they vary in their habitats they do produce a variety of bioactive compounds. The bioactive compounds produced by different species of cyanobacteria are commercially important and used as antibacterial, antiviral, antifungal, enzyme inhibitors, immunostimulants, cytotoxic and antiplasmodium activities. In addition, they are a good source of other important compounds such as vitamins, amino acids, siderophores, simple hydrates etc. The complete genome sequence and molecular biology techniques would be used explore cyanobacteria diversity for the modern civilization and industry.

Keywords: Bioactive compounds; Cyanobacteria

Introduction

Cyanobacteria are a group of oxygenic photosynthetic prokaryotes that grow and multiply at the simple expense of light, H₂O, CO₂ and inorganic nutrients [1]. They are widely distributed in nature, ranging from the Antarctic regions to hot springs, deserts to usar soils and to salt lakes and brine water [2]. Their ability to grow over a wide range of ecological situations such as light, temperature, salinity, alkalinity and pollution makes them model photosynthetic prokaryotes, for the study of various metabolites synthesized by these organisms under such situations [3-5].

The application potential of cyanobacteria in biotechnology is enormous [6] and includes photo-production of NH₄⁺ and hydrogen [7], reclamation of deserts [8], waste water treatment [9], biofertilization of rice agriculture [10], functioning as a bioinsecticide for grazing mosquito larvae [11], and providing a rich source of important pharmaceuticals [12]. The full realization of cyanobacterial potential would possible only when their total knowledge at the molecular level is made available to the industry and modern civilization. Chemoheterotrophic microorganisms namely bacteria and fungi are the traditional source of antibiotics and bioactive compounds. In the late 20th century microalgae have been exploited as a source of biologically active compounds [12]. The biologically active compounds isolated from microalgae are known to show antibacterial, antiviral, antifungal, enzyme inhibitors, immunostimulants, cytotoxic and anti-plasmodium activities

[13,14]. The antimicrobial compounds isolated from microalgae are chemically characterized as polyketides, amides, alkaloids, and peptides [13]. In addition, microalgae are also a good source of other important compounds such as vitamins, amino acids, fatty acids, siderophores, simple hydrates and other compounds that are essential to support the growth of other microorganisms [15].

Bioactive compounds from cyanobacteria

Cyanobacteria such as *Microcystis*, *Anabaena*, *Nostoc* and *Oscillatoria* synthesized varieties of compounds that are biochemically active [16]. Some cyanobacterial species are also known to produce toxic metabolites [17]. The secondary metabolites produced by cyanobacteria are rich sources of novel bioactive compounds applied to the production of medicines and agriculturally important chemicals. Some extracellular metabolites secreted by the cyanobacteria act as toxins or allelochemicals in the natural environment [18]. Cyanobacterial lipopeptides have been identified as interesting biochemically active compounds. Approximately 85% of them are bioactive, including cytotoxic (41%), antitumor (13%), antibiotic (12%), enzyme inhibitor (8%), antiviral (4%) and antifungal activities (4%) [19]. The remaining activity (18%) covers tumor promoting, herbicide, antimycotic, antimitotic, antimalarial, antimicrobial, cell-differentiation promoting activity, cardio activity and UV absorbing activity useable as sunscreens [19].

Cyanobacterial alkaloids isolated from a variety of species show structural diversity and variety of biological actions such as antifungal activity, cytotoxicity, sodium channel modulation, and inhibition of proteases [20,21]. The major sources of these alkaloids are the filamentous genera such as *Lyngbya*, *Oscillatoria*, and *Symploca* [22,23]. Moreover, cyanobacteria are known for the production of toxins associated with water blooms. About 40 genera of cyanobacterial species that are responsible for the production of freshwater and marine cyanobacterial toxins have been reported [23]. These toxins, namely cyanotoxins, can be grouped according to their toxicity in vertebrates as hepatotoxins, neurotoxins, irritants and dermatotoxins, and general cytotoxins [24]. They fall into three broad groups of chemical structures: cyclic peptides, alkaloids and lipopolysaccharides [25,26]. The best known cyanotoxins are microcystins and nodularins, which are potent inhibitors of protein phosphatases.

Together with those toxins, during the last few decades, hundreds of cyanobacterial secondary metabolites were reported [17,27,28,29]. These metabolites possess different chemical structures such as fatty acids, phenolics, terpenoids, N-glycosides, lipopeptides, linear and cyclic peptides and alkaloids. In addition, they exhibit a diverse spectrum of biological activities including antibacterial algicidal, antifungal, antiviral, anticancer, cytotoxic, and enzyme inhibiting activities. Most of the potential bioactive compounds are synthesized from the machinery of non-ribosomal peptide synthetase or mixed with polyketide synthase [30]. Apart from the above bio-synthetic pathway some bioactive compounds such as microviridins and cyanobactins used ribosomal pathways [31]. Therefore, cyanobacteria are considered as a source of potential pharmaceutical substances including antifungal compounds.

Conclusion

Multidrug resistant phenomenon is widespread among the human pathogens. So, it is a demand of the hour to search and develop new drugs from the new source. Now a day cyanobacteria are considered as good candidates to find novel bioactive compounds/drugs. However, all the experiments were performed in vitro; so the in vivo activities of such compounds are questionable. Secondly, the natural products isolated from cyanobacteria are relatively large and not each functional subunit plays vital role in showing the bioactivity, so their commercial production could be possible only after optimizing their chemical structure with organic synthesis methods. In addition, most of the studies confined to characterize the effects of the individual bioactive compound, rather than the effect of various compounds in different combination. This idea will provide a new insight into the synthetic biology.

Acknowledgement

SB thankful to the head department of Botany for providing necessary facilities. SB also thankful to the various staff members for their constant support and encouragement.

References

1. Issa AA, Abd-Alla MH, Ohyama T (2014) Nitrogen fixing cyanobacteria: Future prospect. *Advances in Biology and Ecology of Nitrogen Fixation*. Chapter 2, InTech, Germany, pp. 23-48.
2. Whitton BA, Potts M (2000) Introduction to the cyanobacteria. In: Whitton BA and Potts M (Eds.), *The Ecological of Cyanobacteria*. Kluwer Academic Publishers. The Netherlands, pp. 1-11.
3. Papke RT, Ramsing NB, Bateson MM, Ward DM (2003) Geographical isolation in hot spring cyanobacteria. *Environ Microbiol* 5(8): 650-659.
4. Comte K, Sabacka M, Carre-Mlouka A, Elster J, Komarek J (2007) Relationships between the Arctic and the Antarctic cyanobacteria; three Phormidium-like strains evaluated by a polyphasic approach. *FEMS Microbiol Ecol* 59(2): 366-376.
5. Al-Wathnani H, Johansen JR (2011) Cyanobacteria in soils from a Mojave desert ecosystem. *Monographs Western North American Naturalist*. 5: 71-89.
6. Hall DO, Markov SA, Watanabe Y, Rao KK (1995) The potential applications of cyanobacterial photosynthesis for clean technologies. *Photosyn Res*. 46: 159-167.
7. Markov SA, Lichtl R, Rao KK, Hall DO (1993) A hallow fibre photobioreactor for continuous production of hydrogen immobilized cyanobacteria under partial vacuum. *Int J Hydro Energy* 18: 901-906.
8. Painter TJ (1993) Carbohydrate polymers in desert reclamation: the potential of microalgae biofertilizers. *Carbo Poly* 20: 77-86.
9. Wilde EW, Beneman JR, Weismann JC, Tillen DM (1991) Cultivation of algae and nutrient removal in a waste heat utilization process. *J Appl Phycol* 3: 159-167.
10. Venkataraman GS (1975) The role of blue-green algae in tropical rice cultivation. In: Stewart WDP(Ed.), *Nitrogen fixation by free living microorganisms*, Cambridge University Press, UK, pp. 207-218.
11. Murphy RC, Stevens SE (1992) Cloning and expression of the cryIVD gene of *Bacillus thuringiensis* subsp. *israelensis* in the cyanobacterium *Agenenellum quadraplicatum* PR-6 and its larvicidal activity. *Appl Env Microbiol* 58: 1650-1655.
12. Metting B, Pyne JW (1986) Biological active compounds from microalgae. *Enz Microbial Tech* 8: 386-394.
13. Ghasemi Y, Yazdi MT, Shafiee A, Amini M, Shokravi S, et al. (2004) Parsiguine, a novel antimicrobial substance from *Fischerella ambigua*. *Pharm Biol* 2: 318-322.
14. Dixit RB, Suseela MR (2013) Cyanobacteria: Potential candidates for drug discovery. *Anton Leeuw*. 103: 947-961.
15. Gademann K, Portmann C (2008) Secondary metabolites from cyanobacteria: complex structures and powerful bioactivities. *Curr Org Chem* 12(4): 33-37.
16. Sivonen K, Borner T (2008) Bioactive compounds produced by cyanobacteria. *The Cyanobacteria: Molecular Biology, Genomics and Evolution*. In: Herro A & Flores E (Eds.), Caster Academic Press, Norfolk, UK, pp. 159-197.
17. Carmichael WW (1992) Cyanobacteria secondary metabolites- the cyanotoxins. *J Appl Bacteriol* 72(6): 445-459.
18. Pflungmacher S (2002) Possible allelopathic effects of cyanotoxins, with reference to microcystin-LR, in aquatic ecosystems. *Environ Toxicol* 17(4): 407-413.
19. Burja AM, Banaigs B, Abou-Mansour E, Grant Burgess J, Wright PC (2001) Marine cyanobacteria -a prolific source of natural products. *Tetrahedron* 57(46): 9347-9377.

20. Tan LT (2007) Bioactive natural products from marine cyanobacteria for drug discovery. *Phytochem* 68(7): 954-979.
21. Harvey A (2008) Natural product pharmaceuticals: A diverse approach to drug discovery. *Drug Discovery Today* 13(19-20): 894-901.
22. Williams PG, Yoshida WY, Moore RE, Paul VJ (2001) Isolation and structure determination of obyanamide, a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium *Lyngbya confervoides*. *J Nat Prod* 65(1): 29-31.
23. Grindberg VR, Shuman FC, Sorrels MC, Wingerd J, Gerwick HW (2008) Neurotoxic alkaloids from cyanobacteria. Morden alkaloids: structure, isolation, synthesis and biology. In: Fattorusso E & Tagliatela-Scafati (Eds.), O: Wiley-VCH, USA, 40: 110-112.
24. Sivonen K (2009) Cyanobacterial Toxins. In: Schaechter M (Eds.), *Encyclopedia of Microbiology*, Oxford, Elsevier, UK, pp. 290-307.
25. Jones J, Sivonen K (1999) Cyanobacterial toxins. Toxic cyanobacteria in water: A guide to their public health consequences, monitoring and management. In: Chorus I & Bartram J (Eds.), London: E & FN SPON, pp. 41-111.
26. Stewart I, Schluter PJ, Shaw GR (2006) Cyanobacterial lipopolysaccharides and human health-a review. *Environ Health* 5: 7.
27. Patterson G, Larsen L, Moore R (1994) Bioactive natural products from blue-green algae. *J Appl Phycol* 6(2): 151-157.
28. Harada KI (2004) Production of secondary metabolites by freshwater cyanobacteria. *Chem & Pharma Bull* 82(8): 889-899.
29. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J Nat Prod* 75(3): 311-335.
30. Welker M, von Döhren H (2006) Cyanobacterial peptide-Nature's own combinatorial biosynthesis. *FEMS Microbiol Lett* 30(4): 530-563.
31. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, et al. (2013): Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. *Nat Prod Rep* 30(1): 108-160.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/AIBM.2017.04.555627](https://doi.org/10.19080/AIBM.2017.04.555627)

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>